Led · Equity · Jul 2012

emoquo is a Newbury, UK-based people skills e-learning startup led by Managing Director Kevin Ashley. The company has developed a collection of learning products that organizations stream via desktop, mobile devices, or TV channels. Its content addresses everyday work-related people issues, for example how to have an honest conversation with someone who is underperforming. Clients include a number of blue-chip companies. emoquo closed an £85k SEIS structured investment and intends to use the funding to scale up resources and accelerate growth. Backers include LBA investors.

Participated · Equity · Jun 2012

LumeJet develops a photonics imaging platform originally acquired from a Warwick University spin‑out, engineered to enable high‑precision printed services. Its technology targets photographic media and a range of applications including repro printing, inkless printing, packaging, PCB/photoresist patterning, printed logic and large‑area organic electronics. The company was formed in 2010 and is led by CEO Paul Anson and chairman Christopher McCann. In June 2012 it completed an angel fundraising tranche, part of a larger £4.5m angel round, raising an additional £1.87m. LumeJet says it will use the new capital to expand operations and create 100 new jobs within 2014. The funding and product focus position the company to scale manufacturing and commercial deployments in its target verticals.

Led · Equity · Sep 2011

Momentum Bioscience is developing a suite of technologies called Enzyme Mediated Amplification (EMA) for rapid detection of infection in blood, other normally sterile body fluids, and all living bacteria and fungi. The company is led by Chairman David Evans and CEO Bill Mullen and is based in Reading, UK. Momentum has built prototype products using its EMA platform. The company plans to use the recently raised funds to conduct clinical trials on those prototypes prior to completing product development and launch. The raise indicates an early-stage financing to advance clinical validation. No operating metrics were disclosed in the article.